Orphan drug destination is based more on the disease being targeted and less on the drug. Lots of designations for ovarian cancer have been given this year alone, over a dozen iirc.
Not to downplay the news, I think it's more significant that Cellceutix decided to apply for it than it actually being granted. I.e. Cellceutix saw something they liked rather than the FDA.
News 
Market Data 
Discover 
AI
